Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

This study is testing a combination of an immunotherapy drug (camrelizumab) with chemotherapy (etoposide + cisplatin) as a treatment given before surgery for a rare and aggressive type of cervical cancer called neuroendocrine cervical carcinoma, in women who are candidates for surgery. **You may be eligible if...** - You are a woman aged 18–75 with confirmed neuroendocrine cervical cancer (the neuroendocrine component is more than 60% of the tumor) - Your cancer is at stage I or II and can be surgically removed based on a specialist's assessment - You have at least one measurable tumor - Your blood counts, liver, and kidney function are within acceptable ranges - You are in good general health (ECOG 0–1) **You may NOT be eligible if...** - You have had previous chemotherapy, radiation, or immunotherapy for any cancer - Your cancer has spread to distant organs - You have an active autoimmune disease or history of significant autoimmune conditions - You have HIV/AIDS, organ transplant history, or severe immune deficiency - You are pregnant or breastfeeding - You have significant heart problems or a history of interstitial lung disease Talk to your doctor to see if this trial is right for you.